FDA Approves New Treatment For Type 2 Diabetes
Links shared publicly online about this topic.
- 1,428total visits
FDA Approves New Treatment For Type 2 Diabetes
View full resource at medicalnewstoday.com
Tags: Diabetes, Diabetes Type 2 Medication, Blood Sugar, Type 2 Diabetes, Drug, FDA, Victoza
Most Recently Shared on January 26, 2010 at 3:09 pm By:
FDA Approves New Treatment For Type 2 Diabetes http://mnt.to/3wM5 #diabetes
New Type 2 Diabetes Drug Helps Lower Blood Sugar - Diabetes Center - Everyday Health
everydayhealth.com — “But, FDA wants questions about the drug's long-term safety answered before approval.” View full resource at everydayhealth.com
Most Recently Shared on March 20, 2012 at 7:45 pm By:
New type 2 diabetes drug may help lower blood sugar: http://t.co/SwN0oOeW
FDA approves extended-release tablets for type 2 diabetes - - Drug Topics
drugtopics.modernmedicine.com — “FDA approved sitagliptin and metformin hydrochloride (HCl) extended-release (Janumet XR, Merck) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of Januvia (sitagliptin), with extended-release metformin.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on February 6, 2012 at 2:13 am By:
FDA approves extended-release tablets for type 2 diabetes: FDA approved sitagliptin and metformin hydrochloride ... http://t.co/5Kio7lsL
Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes
news-medical.net — “Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.” View full resource at news-medical.net
Most Recently Shared on January 31, 2012 at 12:29 pm By:
Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes: Boehringer Ingelheim P... http://t.co/QrEPkXXO
FDA Approves BYDUREON™ -- The First Once-Weekly Treatment for Type 2 Diabetes
diabetesincontrol.com — “Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.” View full resource at diabetesincontrol.com
Most Recently Shared on January 28, 2012 at 1:17 pm By:
FDA approves once weekly Bydureon for type 2 diabetes http://t.co/H5WIgIZr
FDA Approves BYDUREON™ — The First and Only Once-Weekly Treatment for Type 2 Diabetes : FDA Approves BYDUREON™ — The First and Only Once-Weekly Treatment for Type 2 Diabetes
dlife.com — “FDA Approves BYDUREON™ — The First and Only Once-Weekly Treatment for Type 2 Diabetes : FDA Approves BYDUREON™ — The First and Only Once-Weekly Treatment for Type 2 Diabetes” View full resource at dlife.com
Most Recently Shared on January 28, 2012 at 4:40 am By:
FDA Approves BYDUREON™ — The First and Only Once-Weekly Treatment for Type 2 Diabetes: January 27, 2012 (Amy... http://t.co/QyYGOtCC
FDA Approves Bydureon - The First and Only Once-Weekly Treatment for Type 2 Diabetes
drugs.com — “Bydureon (exenatide) is used to treat type 2 diabetes. Includes Bydureon side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on January 28, 2012 at 1:49 am By:
FDA Approves Bydureon - The First and Only Once-Weekly Treatment for Type 2 Diabetes - http://t.co/Z0Zr4z1L
U.S. FDA approves Amylin's diabetes drug - Yahoo! News
news.yahoo.com — “From Yahoo! News: WASHINGTON (Reuters) - Amylin Pharmaceuticals Inc won U.S. approval on Friday for its Bydureon diabetes drug, a long-awaited victory for the company's most promising product. After two delays, the Food and Drug Administration approved once-weekly injectable Bydureon for treating adults with Type 2 diabetes, which is linked to poor diet and lack of exercise. Bydureon is a longer-acting form of Amylin's older Byetta treatment. Amylin shares jumped 16.6 percent to $14.16 in after ” View full resource at news.yahoo.com
Most Recently Shared on January 27, 2012 at 11:26 pm By:
U.S. FDA approves Amylin's diabetes drug: WASHINGTON (Reuters) - Amylin Pharmaceuticals Inc won U.S. approval on... http://t.co/5R3g6RBT
Health Highlights: Jan. 27, 2012 --Doctors Lounge
doctorslounge.com — “Health Highlights: Jan. 27, 2012 --Doctors Lounge” View full resource at doctorslounge.com
Most Recently Shared on January 27, 2012 at 10:08 pm By:
Health Highlights: Jan. 27, 2012: FDA Approves New Drug for Type 2 Diabetes Erin Brockovich Takes on High School... http://t.co/IsxFxa4N
F.D.A. Delays Approval of New Diabetes Drug - NYTimes.com
prescriptions.blogs.nytimes.com — “Federal drug regulators are seeking more data from AstraZeneca and Bristol-Myers Squibb before deciding whether to approve dapagliflozin, a new drug aimed at Type 2 diabetes.” View full resource at prescriptions.blogs.nytimes.com
Most Recently Shared on January 20, 2012 at 4:50 pm By:
Scott Strumello Patient Expert
http://t.co/FLXrivWW: FDA Delays Approval of New Type 2 Diabetes Drug http://t.co/R4oNaETg
F.D.A. Delays Approval of New Diabetes Drug - NYTimes.com
prescriptions.blogs.nytimes.com — “Federal drug regulators are seeking more data from AstraZeneca and Bristol-Myers Squibb before deciding whether to approve dapagliflozin, a new drug aimed at Type 2 diabetes.” View full resource at prescriptions.blogs.nytimes.com
Most Recently Shared on January 19, 2012 at 7:20 pm By:
F.D.A. Delays Approval of New Diabetes Drug http://t.co/C3QXhNT9
New Type 2 Drug Targets Blood Sugar and Cholesterol - Diabetes Health
diabeteshealth.com — “Diabetes Health - Research: US Food and Drug Administration. The new therapy, called Juvisync, was just approved by the US Food and Drug Administration. It\'s not a radical new treatment, but instead a helpful combination of two familiar standbys: Juvisync unites the active ingredients in blood sugar-lowering Januvia and cholesterol-lowering Zocor in a single tablet.” View full resource at diabeteshealth.com
Most Recently Shared on December 15, 2011 at 6:11 pm By:
New Type 2 Drug Targets Blood Sugar and Cholesterol - Diabetes Health http://t.co/6i3v3QCT
FDA guidance maps regulatory pathway for artificial pancreas - Related Stories - AdvaMed SmartBrief
smartbrief.com — “The FDA has unveiled draft guidance outlining the process for developing and seeking regulatory approval for artificial pancreas systems, a potential cutting-edge treatment for type 1 diabetes. The guidance aims to provide a clear pathway for the devices from clinical trials to outpatient studies t…” View full resource at smartbrief.com
Most Recently Shared on December 3, 2011 at 12:52 pm By:
#FDA guidance maps regulatory pathway for artificial pancreas http://t.co/ar2smJX9 #nurses #doctors
Byetta Approved as Lantus Add-On :: Diabetes Self-Management
diabetesselfmanagement.com — “On October 19, the US Food and Drug Administration (FDA) approved the Type 2 diabetes medicine Byetta (exenatide) as an add-on treatment to Lantus (insulin glargine) in people who have not achieved blood glucose control with Lantus, diet, and exercise alone...” View full resource at diabetesselfmanagement.com
Most Recently Shared on November 4, 2011 at 3:28 pm By:
Diabetes Self-Mgmt Health Site
#diabetes Byetta has been approved by the FDA as an add-on to Lantus: http://t.co/bu1TmT5z
Medical News: FDA Okays Byetta Plus Insulin Glargine - in Public Health & Policy, FDA General from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved a new indication for the type 2 diabetes drug exenatide (Byetta) as an add-on therapy with insulin glargine, diet, and exercise for adult patients.” View full resource at medpagetoday.com
Most Recently Shared on October 20, 2011 at 6:35 pm By:
FDA okays Byetta plus insulin glargine: http://t.co/SjJfiocG
New Indication for Exenatide : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on October 20, 2011 at 2:18 pm By:
Bob Finn - Medical News Net Health News
FDA: Exenatide (Byetta) approved for adults with type 2 diabetes as an add-on therapy to insulin glargine. http://t.co/DKg62KJu
Advertisement
